Teva has rising revenues and earnings and its stock has been rising over the last four months. Since September 23 the stock has risen from $35 to $48. USB has given Teva a buy rating because it is expected to increase its market share. Teva is well positioned in the United States market and is working on expanding its market share in Europe and in other emerging markets. The company is winning or maintaining leading market positions in Italy, Hungary, the Netherlands, Portugal, Spain and the U.K. The company is forecast to produce double digit earnings thanks to its strong development and acquisitions pipeline.
One of Teva’s stated goals is to become one of the largest pharmaceutical companies in the world. In 2011, Teva acquired Thermax which had many women’s products and marketed them in over 50 countries. This acquisition gave Teva the rights to distribute in growing markets in Spain and Brazil. In 2011, Teva also bought Corporacion Infarmasa, one of the top ten Peruvian drug companies. This company marketed over 500 branded and generic drugs in Peru.
Some of the top directors and managers at Teva Pharmaceuticals are Ron Grupel, Prof. Itzhak Krinsky, Joseph Nitzani, Erez Vigodman, Richard S. Egosi, Uzi Karniel, Ika Abravanel, Ory Slonim, Dr. Gerard W.M. Van Odijk, Amir Elstein, Issac Abravanel, Prof. Moshe Many, Roger Abravanel, Prof. Yitzhak Peterburg, Prof. Roger D. Kornberg, and Frances M. Zipp,
Disclaimer: The information provided here is preliminary information and is insufficient to form investment decisions. All investments should be made only after a thorough investigation of the investment.
Sorry, comments are closed for this post.